Study Focus | Tested compound/ Drug | Methodology | Major Findings | References |
---|---|---|---|---|
Hepatoprotective effects | Bicyclol | Inhibition of hepatocyte apoptosis | No noticeable side effects Increases hepatic heat shock proteins | |
Anticancer activity on HepG2 cells | Cell cycle inhibition autophagy initiation | Inhibits HepG2 cell proliferation, Decreases levels of several key proteins involved in cell cycle and proliferation | [151] | |
Anticancer activity on renal cancer/carcinoma cell | Apoptosis initiation Cell cycle arrest | Increases oxidative stress in cancer cells | [152] | |
Hepatocellular carcinoma | Mice model | Significant reduction in liver tumors; 100% hepatoma and 50% hepatocellular carcinoma in control group | [153] | |
Hepatoprotective and anticancer | ICR mice model with cisplatin | Reduces cisplatin-induced liver tissue damage. Enhances liver enzymes | [154] | |
Multidrug resistance | In vitro studies | Reduces resistance to vincristine and adriamycin in cancer cell lines | [155] | |
Anti-transformative effects | Inhibition of WB-F344 cell transformation | Inhibits malignant transformation of cells | [151] | |
Combination therapies | Wuzhi capsules | Co-administered with methotrexate | Affects Methotrexate pharmacokinetics, suggesting potential to reduce inflammation in immunosuppressive therapies | [152] |
Nephrotoxic and hepatotoxic effects | Co-administered with cyclophosphamide | Potentially attenuates side effects of cyclophosphamide Alters pharmacokinetics to increase drug efficacy | [153] | |
Drug interactions | Co-administered with cyclosporine A, paclitaxel, tacrolimus | Affects blood levels of administered drugs May influence absorption and first-pass metabolism, increasing the oral bioavailability of tacrolimus |